Phase 3 clinical trial of ambroxol for Parkinson's confirmed
Cure Parkinson’s is pleased to announce that a large-scale phase 3 clinical trial of ambroxol, to determine whether the drug can slow the progression of Parkinson’s.
Learn more
An overview of drug development for Parkinson’s
A recently published research report conducted by Parkinson’s research advocates and Cure Parkinson’s presents an encouraging overview of pipeline agents being clinically tested for Parkinson’s.
Ambroxol in Parkinson’s: results of phase 2 trial published
Cure Parkinson’s, in partnership with Van Andel Institute and the John Black Charitable Foundation, is proud to announce the publication of the results of the phase 2 clinical trial that evaluated the safety and tolerability of ambroxol to treat Parkinson’s. The trial background In late…
The lixisenatide trial
Another trial in the promising diabetes drug cohort for repurposing in Parkinson’s is evaluating the effect of lixisenatide on the progression of Parkinson’s. This trial is co-funded by Cure Parkinson’s and Van Andel Institute through the International Linked Clinical Trials programme. This study is being conducted in France…